Bicarbonate

Bicarbonate

SCHEMBL7563121

Cl.O=C(O)O.O=C(O)O.O=C(O)O.O=C(O)O

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.83
CA2 P00918 1/20 0.83
CA9 Q16790 1/20 0.83
FFAR3 O14843 2/20 0.44
ACHE P22303 1/20 0.44
LCK P06239 1/20 0.44
FYN P06241 1/20 0.44
TSHR P16473 4/20 0.36
LMNA P02545 3/20 0.36
LDHA P00338 2/20 0.36
EGLN1 Q9GZT9 2/20 0.36
LDHB P07195 1/20 0.36
SRR Q9GZT4 1/20 0.36
TP53 P04637 1/20 0.36
ALKBH5 Q6P6C2 1/20 0.36
SUCNR1 Q9BXA5 1/20 0.36
EGLN3 Q9H6Z9 1/20 0.36
OR51E2 Q9H255 2/20 0.33
GLRA1 P23415 1/20 0.33
SLC6A9 P48067 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL2523713 1.00
Bicarbonate SCHEMBL18989451 1.00 CA1 (0.83) CA1CA2CA9FFAR3ACHE
Bicarbonate SCHEMBL300524 1.00
Bicarbonate SCHEMBL215876 1.00
Bicarbonate SCHEMBL9467175 1.00
Bicarbonate SCHEMBL7903554 0.93 CA1 (0.71) CA1CA2CA9FFAR3ACHE
Bicarbonate SCHEMBL3265746 0.93
Bicarbonate SCHEMBL6841272 0.93
Bicarbonate SCHEMBL21056250 0.93
Bicarbonate SCHEMBL21056252 0.93

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002068428-A1 METHOD OF PREPARING CEPHALOSPORINS USING 4-HYDROXYPHENYLGLYCINE DERIVATIVES HANMI PHARM. CO., LTD. (KR) 2002-09-06 WO disclosed
US-20020120136-A1 Method of preparing cephalosporins using 4-hydroxyphenylglycine derivatives HANMI PHARM. CO., LTD. (KR) 2002-08-29 US disclosed
US-5438034-A Nonleaching wood preservatives; microbiocides; cationic surfactants LONZA, INC. (US) 1995-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120136-A1 Method of preparing cephalosporins using 4-hydroxyphenylglycine derivatives GYPA, PEPD, HPD CA1 4615/4885CA2 3533/4885CA9 2026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.